Skip to main content
James McKerrow, MD, Pathology, San Francisco, CA, UC San Diego Medical Center - Hillcrest

JamesHMcKerrowMD

Pathology • San Francisco, CA

Anatomic Pathology, Clinical Pathology

Professor, Pathology, UCSF School of Medicine

Join to view full profile

Are you Dr. McKerrow?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 29 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. James McKerrow, MD is a board certified pathologist in San Francisco, California. He is currently licensed to practice medicine in California. He is affiliated with UC San Diego Medical Center - Hillcrest and is a Professor at UCSF School of Medicine.

Education & Training

  • University of California (San Francisco)
    University of California (San Francisco)Residency, Pathology-Anatomic and Clinical, 1977 - 1978
  • Stony Brook Medicine/University Hospital
    Stony Brook Medicine/University HospitalInternship, Internal Medicine, 1976 - 1977
  • Stony Brook University Health Sciences Center School of Medicine
    Stony Brook University Health Sciences Center School of MedicineClass of 1976

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1977 - 2026
  • American Board of Pathology Anatomic Pathology

Publications & Presentations

PubMed

Press Mentions

  • Experimental Therapy for Parasitic Heart Disease – K777 – May Also Help Stop COVID-19
    Experimental Therapy for Parasitic Heart Disease – K777 – May Also Help Stop COVID-19April 6th, 2021
  • Selva Raises $3m to Develop Novel Antiviral Against Covid-19
    Selva Raises $3m to Develop Novel Antiviral Against Covid-19August 12th, 2020
  • Broad Spectrum Antiviral Oral Therapy Demonstrates High Potency Against COVID-19 in in Vitro Triggering Investor Demand to Fund Series A Round in Selva Therapeutics
    Broad Spectrum Antiviral Oral Therapy Demonstrates High Potency Against COVID-19 in in Vitro Triggering Investor Demand to Fund Series A Round in Selva TherapeuticsJuly 21st, 2020
  • Join now to see all

Grant Support

  • LEAD Identification To Clinical Candidate Selection: Drugs For Chagas DiseaseNational Institute Of Allergy And Infectious Diseases2010–2011
  • Hydrolysis Of Hemoglobin By Schistsoma Mansoni Cathepsin B-Like CysteineproteaseNational Center For Research Resources2010–2011
  • Proteomics Analysis Of Schistosome Host-Invasion And MetabolismNational Center For Research Resources2005–2011
  • Giardia Lamblia Cysteine Proteases: Trafficking, Localization, And FunctionNational Center For Research Resources2005–2011
  • Structure Based Drug Design For Treatment Of Parasitic And Viral DiseasesNational Center For Research Resources2004–2011
  • Mechanism Of Host Invasion By SchistosomesNational Center For Research Resources2004–2011
  • Hydrolysis Of Hemoglobin By Schistsoma Mansoni Cathepsin B-Like Cysteine ProteaNational Center For Research Resources2005–2009
  • Targeting Cysteine Proteases: Antiparasitic ChemotherapyNational Institute Of Allergy And Infectious Diseases2004–2008
  • Parasitology And Cell BiologyNational Institute Of Allergy And Infectious Diseases2004–2008
  • Host Protein Degradation By Schistosome ParasitesNational Institute Of Allergy And Infectious Diseases2003–2007
  • High Throughput Assay For Screening Compounds(Rmi)National Institute Of Neurological Disorders And Stroke2005
  • Predoctoral Training In Biomedical SciencesNational Institute Of General Medical Sciences2002–2005
  • Hydrolysis Of Hemoglobin By Schistsoma Mansoni Cathepsin B-Like Cysteine ProteasNational Center For Research Resources2004
  • Targeting Cysteine Proteases--Antiparasitic ChemotherapyNational Institute Of Allergy And Infectious Diseases1999–2003
  • Core--Microscopy And Advanced Imaging FacilityNational Institute Of Diabetes And Digestive And Kidney Diseases2002
  • Core--Inhibitor Screens, Cell Biology, And ParasitologyNational Institute Of Allergy And Infectious Diseases1999–2002
  • Core--BiochemistryNational Cancer Institute1997–2002
  • Serologic Marker Of Exposure To Schistosome ParasitesNational Center For Research Resources1998–2001
  • Molecular Signals For Granuloma FormationNational Center For Research Resources1998–2001
  • Cercarial Proteinase Of Schistosoma MansoniNational Center For Research Resources1998–2001
  • Interdisciplinary Drug Design Targeting T Cruzi ProteaseNational Center For Research Resources1996–2001
  • Proteases In Cancer: Biology &Drug DevelopmentNational Center For Research Resources1998–1999
  • Serologic Marker Of Exposure To Schistosome ParasitesNational Institute Of Allergy And Infectious Diseases1997–1998
  • Interdiscipilinary Drug Design Targeting A T CruziNational Institute Of Allergy And Infectious Diseases1995–1998
  • Characterization Of Cercarial Proteinase Of S MansoniNational Center For Research Resources1997
  • Cercarial Proteinase Of Schistosoma MansoniNational Institute Of Allergy And Infectious Diseases1993–1997
  • Cysteine Proteases In FilariaeNational Center For Research Resources1996
  • Characterization Of Cercariae Proteinase Of S MansoniNational Center For Research Resources1996
  • Characterization Of Cercarial Proteinase Of S MansoniNational Institute Of Allergy And Infectious Diseases1990–1992
  • Characterization Of Cercarial Proteinase Of S MansoniNational Institute Of Allergy And Infectious Diseases1987–1989
  • Proteolytic Activity Of The Larvae Of S. MansoniNational Institute Of Allergy And Infectious Diseases1985

Hospital Affiliations

Dr. James McKerrow, Dr. James McKerrow, MD, Dr. J McKerrow, Dr. James H McKerrow